Preliminary results from a phase 1/2 study of INCB054828, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced malignancies

被引：8
作者：
Saleh, Mansoor
Gutierrez, Martin E.
Subbiah, Vivek
Smith, David C.
Asatiani, Ekaterine
Lihou, Christine F.
Zhen, Huiling
Yeleswaram, Swamy
Ji, Tao
Nemunaitis, John
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-CT111
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT111
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Pharmacokinetics and pharmacodynamics of pemigatinib, a potent and selective inhibitor of FGFR 1, 2, and 3, in patients with advanced malignancies
    Ji, Tao
    Lihou, Christine
    Asatiani, Ekaterine
    Feliz, Luis
    Overholt, Heather
    Landman, Robert
    Chen, Xuejun
    Yeleswaram, Swamy
    [J]. MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [32] Trial design for a phase 3 study evaluating pemigatinib (INCB054828) versus gemcitabine plus cisplatin chemotherapy in first-line treatment of patients with cholangiocarcinoma with FGFR2 rearrangement.
    Bekaii-Saab, Tanios S.
    Valle, Juan W.
    Borad, Mitesh J.
    Melisi, Davide
    Vogel, Arndt
    Feliz, Luis
    Lihou, Christine Francis
    Zhen, Huiling
    Abou-Alfa, Ghassan K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [33] Exploratory biomarker analysis of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors.
    Kilgour, Elaine
    Ferry, David
    Saggese, Matilde
    Arkenau, Hendrik-Tobias
    Rooney, Claire
    Smith, Neil R.
    Baker, Dawn
    Dougherty, Brian
    Womack, Chris
    Smith, Paul D.
    Ghiorghiu, Dana C.
    Harrington, Elizabeth A.
    Barrett, J. Carl
    Brooks, Nigel
    Stockman, Paul
    Andre, Fabrice
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] Results from a Phase 1/2 Study of INCB050465, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies (CITADEL-101)
    Forero-Torres, Andres
    Ramchandren, Rod
    Yacoub, Abdulraheem
    Wertheim, Michael S.
    Edenfield, William J.
    Caimi, Paolo
    Gutierrez, Martin
    Akard, Luke
    Escobar, Carolina
    Call, Justin
    Persky, Daniel
    Iyer, Swami P.
    DeMarini, Douglas J.
    Zhou, Li
    Yeleswaram, Swamy
    Phillips, Tycel J.
    [J]. BLOOD, 2017, 130
  • [35] Phase 2, open-label, multicenter study of the efficacy and safety of INCB054828 in patients (pts) with advanced, metastatic, or surgically unresectable cholangiocarcinoma (CCA) with inadequate response to prior therapy
    Borad, Mitesh J.
    Davis, S. Lindsey
    Lowery, Maeve A.
    Asatiani, Ekaterine
    Lihou, Christine F.
    Zhen, Huiling
    Abou-Alfa, Ghassan K.
    [J]. CANCER RESEARCH, 2017, 77
  • [36] Phase 1, first-in-human study of ARQ 087, an oral pan-Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors.
    Papadopoulos, Kyriakos P.
    Tolcher, Anthony W.
    Patnaik, Amita
    Rasco, Drew Warren
    Chambers, Glenda
    Beeram, Murali
    Savage, Ronald
    Hall, Terence
    Schwartz, Brian E.
    Kazakin, Julia
    LoRusso, Patricia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] A phase 1 expansion cohort of the fibroblast growth factor receptor (FGFR) inhibitor AZD4547 in patients (pts) with advanced gastric (GC) and gastroesophageal (GOJ) cancer
    Arkenau, Hendrik-Tobias
    Saggese, Matilde
    Hollebecque, Antoine
    Mathewson, Alastair
    Lemech, Charlotte Rose
    Landers, Donal
    Frewer, Paul
    Kilgour, Elaine
    Brooks, Nigel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [38] Phase 2, open-label, multicenter study of the efficacy and safety of INCB054828 in patients (pts) with advanced, metastatic, or surgically unresectable cholangiocarcinoma (CCA) with inadequate response to prior therapy.
    Borad, Mitesh J.
    Davis, Sarah Lindsey
    Lowery, Maeve Aine
    Lihou, Christine F.
    Abou-Alfa, Ghassan K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [39] Phase I study of LY2874455, a fibroblast growth factor (FGF) receptor inhibitor, in patients with advanced cancer
    Tie, Jeanne
    Bang, Yung-Jue
    Park, Young Suk
    Kang, Yoon-Koo
    Monteith, David
    Hartsock, Kimberly
    Hamid, Oday
    Thornton, Donald E.
    Michael, Michael
    [J]. CANCER RESEARCH, 2016, 76
  • [40] First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors
    Dienstmann, Rodrigo
    Bahleda, Rastilav
    Adamo, Barbara
    Rodon, Jordi
    Varga, Andrea
    Gazzah, Anas
    Platero, Suso
    Smit, Hans
    Perera, Timothy
    Zhong, Bob
    Stuyckens, Kim
    Elsayed, Yusri
    Takimoto, Chris
    Peddareddigari, Vijay
    Tabernero, Josep
    Luo, Feng Roger
    Soria, Jean-Charles
    [J]. CANCER RESEARCH, 2014, 74 (19)
12345